Casgevy gains FDA pediatric approval, boosting Crispr Therapeutics' market and stock to 4-month high.
Crispr Therapeutics received FDA approval for Casgevy in pediatric patients, expanding its potential market and reinforcing its leadership in gene editing. Despite initial slow sales due to treatment complexity and cost, Casgevy's strong clinical res...
